Squamous in Medical Technology

Prometheus and Rosetta Genomics Announce License and Collaboration Agreement

... diagnostic tests: miRview(TM) mets, miRview(TM) squamous and miRview(TM) meso. The terms of the ... primary origin. About miRview(TM) squamous Using a single microRNA, miRview(TM) squamous is designed to ...

Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests

... our proprietary microRNA technology. miRview(TM) squamous offers physicians a standardized, quantitative ... of 97%, and a specificity of 91% in identifying squamous cell lung cancer. Classification accuracy was ... Genomics Chief Scientific Office." miRview(TM) squamous is designed to offer a quantitative, objective, ...

Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer

... the DMC recommended that the patients with squamous NSCLC immediately discontinue motesanib therapy ... with advanced NSCLC. Patients with either squamous or non-squamous NSCLC were allowed in this study. squamous NSCLC is a histological subtype of NSCLC and ...

Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay

... miRview(TM) Squamous, Which Differentiates squamous From non squamous non Small Cell Lung Cancer, With Current ... Genomics is Expecting to Launch miRview(TM) squamous Later This Year Through its Recently ...

First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval

... MicroRNA Technology The Test Differentiates squamous From Non-Squamous Non-Small Cell Lung Cancer ... of severe or fatal hemorrhage among patients with squamous NSCLC histology compared with non-squamous NSCLC. ... percent of the time. Furthermore, sensitivity for squamous cell carcinoma was only 70.9 percent(2). A ...

Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica

... Test is Designed to Differentiate squamous From Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Classifying squamous Cell Carcinoma of the Lung With Sensitivity of ... of Severe or Fatal Hemorrhage in Patients With squamous NSCLC Histology. ...

Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine

... (OS) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) are ... with unresectable locoregionally advanced squamous cell carcinoma have always been low. These data ... treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). ...

Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes

... the analysis suggested that patients with a squamous histology and treated with docetaxel had ... [95% CI 1.079, 2.264]). Patients with a non- squamous histology represented the majority of the ... Adenocarcinoma and Large Cell Lung Cancer than in squamous Cell Carcinoma? A Retrospective Analysis of ...

ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study

... the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck. ERBITUX as a ... of patients with recurrent or metastatic squamous cell carcinoma of the head and neck for whom ... death occurred in 2% (4/208) of patients with squamous cell carcinoma of the head and neck treated ...

CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series

... disease management in newly diagnosed (treatment naive) patients with squamous Cell Carcinoma of the Head and Neck. Early intervention in this disease ... collected from patients with advanced primary Head and Neck cancer (Oral squamous Cell Carcinoma) during the impending Multikine Pivotal Global Phase III ...

Researchers at the Karmanos Cancer Institute in Detroit Discover Feasibility of Chemotherapy Alternative

... and cancer metastases in patients with locally advanced head and neck squamous cell carcinoma. The findings were announced today at the 2009 American ... rate for the tumors." Approximately 40,000 new cases of head and neck squamous cell carcinoma (HNSCC) cases are diagnosed each year, according to Dr. ....

Independent Data Monitoring Committee Recommends Resuming Enrollment of Non-Squamous NSCLC Patients in the Motesanib MONET1 Trial

... 2008 the DMC recommended treatment discontinuation in subjects with squamous histology, and enrollment suspension in subjects with non-squamous ... compared to the placebo group and a higher incidence of hemoptysis in the squamous population. Patients with non-squamous NSCLC receiving motesanib were ...

CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect

... genomic differences in the tumor microenvironment in patients with squamous cell carcinoma of the head and neck. Should these pre-clinical experiments ... and granted orphan drug status to Multikine for the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck, in May 2007. In the summer ...

Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)

... 6. "MicroRNAs as a diagnostic tool for differentiating squamous cell lung cancer from other non small cell lung cancers" Lung cancer is ... potential higher rates of severe or fatal hemorrhage in patients with squamous NSCLC histology. 7. "Differential diagnosis of mesothelioma using a ...

Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers

... Responses were particularly encouraging in primary liver (HCC) cancers, squamous cell cancers (including lung) and melanoma. All three patients with ... liver cancer is currently being initiated. A Phase 2 trial for JX-594 in squamous cell head and neck cancer is expected to begin in the first quarter of ...

DAHANCA Initiates Head and Neck Cancer Study With Genmab's HuMax-EGFr

... of HuMax-EGFr in combination with radiotherapy in treating patients with squamous cell carcinoma of the head and neck. The primary endpoint is ... affect the mouth, nasal cavities, sinuses, larynx and pharynx. Most are squamous carcinomas but others include lymphoepithelioma and lymphoma. Head and ...

First Skin Cancer Patients Treated With Electronic Brachytherapy (eBx) At University of Wisconsin Riverview Cancer Center

... the most serious form of skin cancers, it accounts for less than 10 percent of all cases. Non-melanoma skin cancers, such as basal cell carcinoma and squamous cell carcinoma, represent the majority of all new cases. "We are dedicated to bringing the most complete and innovative cancer care to ...

Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer

... IB trial (Dipetrillo,Thomas et al, Am. J. Clin. Oncol. 4:376-9 (2006)), patients with pathologically confirmed, locally advanced adenocarcinoma or squamous cell carcinoma of the esophagus or gastro-esophageal junction with no evidence of distant metastasis received weekly paclitaxel poliglumex (50mg/m2) ...

Encouraging First Data on New Targeted Treatment for Patients With Melanoma - the Deadliest Form of Skin Cancer

... adverse events, including rash and photosensitivity, have been classified as mild in grade. Serious adverse events, including diagnosis of cutaneous squamous cell carcinoma, were observed in some patients after chronic treatment; however the safety profile has been warranted favourable for this population ...

Induction Chemotherapy Followed by ChemoRadiotherapy Increased Time-to-Treatment Failure Compared to ChemoRadiotherapy Alone in Patients With Unresectable Locally Advanced Head & Neck Cancer

... will die from the disease. Head and neck cancer is a group of tumors that mostly arise in the cells that line the mucosal surfaces, giving rise to squamous cell carcinoma in the head and neck area, such as the mouth, tongue, tonsils, voice box and throat. "This trial showed that adding Induction ...

BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting

... in an abstract (number 6018) entitled, "Phase I/II dose escalation study of OncoVEX GM-CSF and chemoradiotherapy (CRT) in untreated stage III/IV squamous cell cancer of the head and neck (SCCHN)," at a poster session on Friday, May 29, 2009 from 2:00pm - 6:00pm EDT on Level 2, West Hall F3 of the ...

Clinician Reports Fast Healing of Intractable Wounds Using MEDIHONEY(R)

... Active Leptospermum Honey: Treatment for Various Lower Extremity Dermatologic Issues (Tracey Vlahovic, Temple University , PA) squamous Cell Carcinoma of the Head and Neck: Using Active Leptospermum Honey for Wound Management and Odor Control (Scott Moore, Edmund Oncology ...

CEL-SCI Corporation Releases Letter to Shareholders

... (FDA) has given the go-ahead for a Phase III clinical trial with Multikine and granted orphan drug status to Multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck. Most recently CEL-SCI completed construction of the manufacturing facility to produce Multikine for ...

Cancer Therapy & Research Center at The University of Texas Health Science Center and Oncolytics Biotech(R) Inc. Announce Multi-Trial Clinical Research Collaboration

... REOLYSIN(R) in combination with chemotherapy for various cancer indications. These indications are expected to include melanoma, pancreatic cancer, squamous cell lung, liver and K-RAS mutated colorectal cancers in combination with standard chemotherapeutics. This research program is in addition to Phase 2 ...

CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine

... (FDA) gave the go-ahead for a Phase III clinical trial with Multikine and granted orphan drug status to Multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck. Multikine is also the first immunotherapeutic agent being developed as a first-line standard of care ...

MicroRNA First Disclosed by Rosetta Genomics may Increase Efficacy of Imatinib (Gleevec(R)(1)) in Glioblastoma

... primarily on cancer and various women's health indications. The first test based on the company's technology, differentiating squamous from non squamous non small cell lung cancer, is now approved through Columbia University Medical Center's High Complexity Molecular Pathology Laboratory. In Addition, ...

CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008

... the go-ahead for a Phase III clinical trial with Multikine in January 2007 and granted orphan drug status to Multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck in May 2007. In the summer of 2007 CEL-SCI started construction of the manufacturing facility to produce ...

Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum

... primarily on cancer and various women's health indications. The first test based on the company's technology, differentiating squamous from non squamous non small cell lung cancer, is now approved through Columbia University Medical Center's High Complexity Molecular Pathology Laboratory. In Addition, ...

Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting

... leukemia in chronic phase (Abstract #7010: Monday, June 2; 10:30 AM - 10:45 AM CDT). -- Phase II data comparing safety and efficacy between squamous and non-squamous non-small cell lung cancer patients receiving ASA404 (Abstract #8072: Sunday, June 1, 2008; 2:00 PM-6:00 PM CDT). Novartis ...

Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial

... 1.2 million women are diagnosed with low grade cervical dysplasia (CIN 1), 300,000 with high grade dysplasia (CIN 2/3) and 2.4 million with atypical squamous cells of undetermined significance (ASCUS). No therapies other than surgery are currently approved by the FDA for the treatment of any type of CIN. ...

Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Company's MicroRNA Technology

... relating to the development and validation of diagnostic tests based on the company's microRNA technology. The tests are designed to differentiate squamous versus non-squamous lung cancer, differentiate mesothelioma from adenocarcinoma, and identify cancers of unknown primary (CUP) origin. "This ...

Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial

... 1.2 million women are diagnosed with low grade cervical dysplasia, (CIN 1), 300,000 with high grade dysplasia (CIN 2/3) and 2.4 million with atypical squamous cells of undetermined significance (ASCUS). No therapies other than surgery are currently approved by the U.S. Food and Drug Administration (FDA) for ...

GSK Cervical Cancer Candidate Vaccine CERVARIX (R) Demonstrates Long-Term Protection for More Than Six Years

... at: SGO's Annual Meeting on Women's Cancer. March 10, 2008 (5) Bulk S, Berkhof J, Bulkmans NW, et al. Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands. Br J Cancer. ...

CEL-SCI Corporation Reports First Quarter Financial Results

... the go-ahead for a Phase III clinical trial with Multikine in January 2007 and granted orphan drug status to Multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck in May 2007. CEL-SCI is currently building a manufacturing facility for Multikine close to Baltimore, ....

CEL-SCI Corporation Announces 2007 Financial Results

... the go-ahead for a Phase III clinical trial with Multikine in January 2007 and granted orphan drug status to Multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck in May 2007. Multikine, a patented defined mixture of naturally derived cytokines, is the first ...

CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference

... the go-ahead for a Phase III clinical trial with Multikine in January 2007 and granted orphan drug status to Multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck in May 2007. Multikine, a patented defined mixture of naturally derived cytokines, is the first ...

Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery

... has approved Taxotere(R) (docetaxel) Injection Concentrate in combination with cisplatin and 5-fluorouracil for induction therapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN) before patients undergo chemoradiotherapy and surgery. The FDA based its approval on the results of the ...

Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

... of Lung Cancer grows and spreads more slowly than small cell lung cancer. Non-small cell lung cancer is divided into three different subcategories. squamous cell carcinoma originates in the thin, flat cells that line the passages of the respiratory tract. Adenocarcinoma begins in the cells that form the ...

CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug

... the go-ahead for a Phase III clinical trial with Multikine in January 2007 and granted Orphan drug status to Multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck in May 2007. Multikine, a patented defined mixture of naturally derived cytokines, is the first ...